SHIFTBIO’s Cell-Free Nanotherapy Platforms and Programs aim to treat rare and intractable diseases with high unmet medical needs.

 Lead program    Pre-clinical    IND Filing    Clinical data

Platform

Maxisome

Program

SBI-101

Indication

Immunotherapy resistant
solid tumor

Mechanism

CD47 Degradation-Induced 

Anti-tumor Immunity

Right
SHIFTBIO
Expected Clinical Milestones
2024
2025
2026

Platform

Maxisome

Program

SBI-102

[SIRP-NV]

Indication

Acute Organ Injury Fibrosis/NASH

Mechanism

CD47 Degradation-Induced
Regenerative Immunity

Right
SHIFTBIO
Expected Clinical Milestones
2024
2025
2026

Platform

Maxisome

Program

SBI-104

Indication

Pulmonary Arterial Hypertension

Mechanism

Anti-proliferation and Vasodilation

Right
SHIFTBIO/KIST
Expected Clinical Milestones
2024
2025
2026

Platform

InProDel

Program

SBI-201 
[HIF1α-NV]

Indication

Undisclosed

Mechanism

Activating Resolutive Immunity 

Right
SHIFTBIO
Expected Clinical Milestones
2024
2025
2026

Platform

Fusosome

Program

SBI-301

Indication

Immunotherapy Resistant
Solid Tumor

Mechanism

Cancer Cell Membrane Editing

Right
SHIFTBIO
Expected Clinical Milestones
2024
2025
2026



Platform

Fusosome

Program

SBI-302

Indication

Immunotherapy Resistant
Solid Tumor

Mechanism

Immunogenic Cancer Cell Death

Right
SHIFTBIO
Expected Clinical Milestones
2024
2025
2026



Platform

InProDel

Program

SBI-303 

Indication

Personalized Cancer Vaccine

Mechanism

mRNA Delivery

Right
SHIFTBIO
Expected Clinical Milestones
2024
2025
2026

SHIFTBIO’s Cell-Free Nanotherapy Platform Technologies and Programs
aim to treat rare and intractable diseases with high unmet medical needs.

 Lead program    Pre-clinical     IND Filing     Clinical data


Platform


Program

Indication

Mechanism

Expected Clinical Milestones

Rights

2024

2025

2026

Maxisome

SBI-101

Immunotherapy 

Resistant Solid Tumor

CD47 Degradation-Induced 

Anti-tumor Immunity

SHIFTBIO

SBI-102

[SIRP-NV]

Acute Organ Injury

Fibrosis/NASH

CD47 Degradation-Induced Regenerative Immunity

SHIFTBIO

SBI-104

Pulmonary Arterial Hypertension

Anti-proliferation 

and Vasodilation

SHIFTBIO

/KIST

InProDel

SBI-201

[HIF1α-NV]

Undisclosed

Activating 

Resolutive Immunity

SHIFTBIO

Fusosome

SBI-301

Immunotherapy 

Resistant Solid Tumor

Cancer Cell 

Membrane Editing




SHIFTBIO

SBI-302

Immunotherapy 

Resistant Solid Tumor

Immunogenic 

Cancer Cell Death




SHIFTBIO

SBI-303

Personalized 

Cancer Vaccine

mRNA Delivery


SHIFTBIO